Every material Form 8-K Shattuck Labs, Inc. has filed with the SEC since June 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Shattuck Labs reported a third-quarter 2026 net loss of $25.2 million, or $0.14 per share, up from $10.1 million a year earlier, as research and development spending rose to $21.6 million from $7.6 million. The company had no revenue in the quarter, compared with $1.0 million of related party license revenue a year earlier, and said its $196.3 million in cash, cash equivalents and short-term investments should fund operations into 2029.
Net loss of $25.2 million, or $0.14 per share, for the quarter ended September 30, 2026, versus a net loss of $10.1 million, or $0.14 per share, a year earlier.
R&D expenses were $21.6 million versus $7.6 million; there was no license revenue in Q3 2026 compared with $1.0 million in Q3 2025.
Cash, cash equivalents and short-term investments were $196.3 million at September 30, 2026, versus $86.1 million a year earlier.
RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease was initiated; RECEPTIVE-HS1 Phase 2 trial start is expected in Q4 2026.
Shattuck Labs reported no revenue for the quarter ended June 30, 2026, and a net loss of $15.2 million, up from $12.5 million a year earlier. Loss per share narrowed to $0.12 from $0.24, while the weighted-average share count rose to about 129.8 million from about 51.0 million. Cash, cash equivalents and short-term investments were $208.3 million, which the company says should fund operations into 2029.
Net loss was $15.2 million, or $0.12 per share, for Q2 2026, versus $12.5 million, or $0.24 per share, for Q2 2025.
R&D expenses rose to $11.7 million from $8.7 million; G&A expenses were $4.5 million versus $4.4 million.
Cash and short-term investments were $208.3 million at June 30, 2026, versus $50.5 million a year earlier.
The RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease is expected to start in Q3 2026; the company also cites a $86.2 million underwritten offering and $57.1 million from warrant exercises.
Shattuck Labs entered into an underwriting agreement on June 9, 2026, for an underwritten public offering of common stock and pre-funded warrants, with the offering expected to close on June 11, 2026. The sale of new shares and warrants would add to the shares outstanding, which affects existing shareholders' ownership percentage.
Underwriting agreement dated June 9, 2026, with Leerink Partners, J.P. Morgan Securities, Piper Sandler and Cantor Fitzgerald as representatives
Offering of 10,879,376 common shares at $4.00 per share, plus pre-funded warrants for 7,870,624 shares at $3.9999 per share
Underwriters' 30-day option for up to 2,812,500 additional shares was exercised in full on June 10, 2026
Offered under a shelf registration statement (File No. 333-292697) effective January 21, 2026; closing expected June 11, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Shattuck Labs, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →